By Frank Prenesti
Date: Tuesday 28 Jan 2025
(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu has been approved in the US for the treatment of adults with HER2 breast cancer, after disease progression having had one or more hormone therapies.
The approval was granted by the Food and Drug Administration based on results from the DESTINY-Breast06 phase 3...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news